BRPI1013992A2 - compositions and methods for treating insulin resistance and diabetes mellitus - Google Patents

compositions and methods for treating insulin resistance and diabetes mellitus

Info

Publication number
BRPI1013992A2
BRPI1013992A2 BRPI1013992A BRPI1013992A BRPI1013992A2 BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2 BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
diabetes mellitus
insulin resistance
treating insulin
Prior art date
Application number
BRPI1013992A
Other languages
Portuguese (pt)
Inventor
Anthony B Wood
Gregory J Archambeau
Richard L Watson
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of BRPI1013992A2 publication Critical patent/BRPI1013992A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1013992A 2009-04-27 2010-04-27 compositions and methods for treating insulin resistance and diabetes mellitus BRPI1013992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (1)

Publication Number Publication Date
BRPI1013992A2 true BRPI1013992A2 (en) 2016-08-16

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013992A BRPI1013992A2 (en) 2009-04-27 2010-04-27 compositions and methods for treating insulin resistance and diabetes mellitus

Country Status (9)

Country Link
EP (1) EP2424507A4 (en)
JP (2) JP2012525396A (en)
CN (1) CN102413817B (en)
AU (1) AU2010241736B2 (en)
BR (1) BRPI1013992A2 (en)
CA (1) CA2758738A1 (en)
IL (1) IL215925A0 (en)
MX (1) MX2011011333A (en)
WO (1) WO2010126908A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711558A2 (en) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
PT2600812T (en) 2010-08-05 2021-11-09 Forsight Vision4 Inc Implantable therapeutic device
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
MX371198B (en) * 2010-11-15 2020-01-22 Boehringer Ingelheim Int VASOPROTECTIVE and CARDIOPROTECTIVE ANTIDIABETIC THERAPY.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2696849A4 (en) * 2011-04-13 2014-10-29 Revalesio Corp COMPOSITIONS AND METHODS FOR INHIBITING AND / OR MODULATING T EFFECTOR LYMPHOCYTES IN INFLAMMATORY NEURODEGENERATIVE DISEASE
WO2013003620A2 (en) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
ES2864203T3 (en) 2011-09-16 2021-10-13 Forsight Vision4 Inc Fluid exchange apparatus
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
CH706747A2 (en) * 2012-07-17 2014-01-31 Hanspeter Steffen Process for hydration, tightening and care of the skin, for the treatment of dermatoses, sunburn and general wounds with electrolysis water produced with diamond electrodes.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105246438B (en) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 Ophthalmic implants for delivery of therapeutic substances
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
WO2015099201A1 (en) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 Nanobubble-containing composition and use thereof
MX384889B (en) 2014-07-15 2025-03-14 Forsight Vision4 Inc OCULAR IMPLANT DELIVERY DEVICE AND METHOD.
KR20170040798A (en) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
EP3217924B1 (en) 2014-11-10 2025-07-16 ForSight Vision4, Inc. Expandable drug delivery devices
JP6674748B2 (en) * 2015-05-27 2020-04-01 花王株式会社 GLP-1 secretagogue
KR20180084104A (en) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN105878194A (en) * 2016-06-07 2016-08-24 沈阳药科大学 Glibenclamide nanocrystal preparation and preparation method thereof
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 Combination of linagliptin and metformin
CN106362166B (en) * 2016-10-27 2019-12-10 武汉大学 Function and application of tumor necrosis factor receptor-related pan-scaffold and signaling protein in treatment of fatty liver and type II diabetes
CN115607358A (en) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 Fluid exchange device for expandable port delivery system and method of use
CN110006871A (en) * 2019-02-20 2019-07-12 常州大学 A cellular model based on exogenous histamine detection and its application
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (en) * 1990-10-02 1992-04-16 Buchholz Klaus L Use of the reaction product of a gas and a liquid, as well as process and device for producing the same
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
ATE372124T1 (en) * 2001-02-01 2007-09-15 Hydron Technologies Inc COMPOSITION AND METHOD FOR PERCUTANE SUPEROXYGENATION
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20060275189A1 (en) * 2005-06-03 2006-12-07 BAGLEY David Apparatus for generating structured ozone
EP2086668B1 (en) * 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
AU2007308840C1 (en) * 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (en) * 2006-12-26 2008-07-10 Hydrox Kk Antioxidant functional water
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
CN101910412B (en) * 2007-10-25 2013-08-21 利发利希奥公司 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Also Published As

Publication number Publication date
AU2010241736B2 (en) 2016-01-28
JP2012525396A (en) 2012-10-22
IL215925A0 (en) 2011-12-29
EP2424507A4 (en) 2012-10-24
WO2010126908A1 (en) 2010-11-04
EP2424507A1 (en) 2012-03-07
CA2758738A1 (en) 2010-11-04
CN102413817B (en) 2014-12-17
AU2010241736A1 (en) 2011-12-22
CN102413817A (en) 2012-04-11
MX2011011333A (en) 2011-11-18
JP2015229678A (en) 2015-12-21

Similar Documents

Publication Publication Date Title
NO2024044I1 (en) Insulin icodec
IL215925A0 (en) Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus
BRPI0910282A2 (en) Oxadiazo-anthracene compound for diabetes treatment
HUE038279T2 (en) Clotho-beta agonist antibody for use in the treatment of diabetes or insulin resistance
BRPI0716134A2 (en) combination treatment for diabetes mellitus
BRPI1012642A2 (en) insulin formulation and method for treating a diabetic individual.
DK2252312T3 (en) Methods for preventing or treating insulin resistance
BRPI0911782A2 (en) super fast acting insulin composition
FI20096188A0 (en) Nutrigenetic biomarkers for obesity and type 2 diabetes
BRPI0908416A2 (en) Injection Syringe
BRPI1006145A2 (en) "composition and method for treating diabetes".
EP2367541A4 (en) CONTROLLED RELEASE COMPOSITION PREVENTING MISUSE
EP2409997A4 (en) REDOX CURED TYPE COMPOSITION
DK3181134T3 (en) BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS
IL205554A (en) An insulin resistance treatment containing melanocortin
BRPI0815760A2 (en) INJECTABLE DERMATOLOGICAL COMPOSITION FOR WRINKLE TREATMENT
BRPI0813909A2 (en) Syringe with Disable Mechanism
BR112012000502A2 (en) combination therapy for diabetes treatment
BRPI0919288A2 (en) combination therapy for treatment of diabetes and related conditions.
BRPI0822830A2 (en) Disable mechanism syringe
BRPI0906094A2 (en) Type II Diabetes Compound and Treatment Method
BRPI0810525A2 (en) COMPOSITIONS AND METHODS FOR PROPHYLAXY AND CHEMICAL DEPENDENCE TREATMENT
DK2328636T3 (en) DEVICE FOR IMPROVED SUBCUTAN INSULIN ABSORPTION
BRPI0911083A8 (en) methods for treating or preventing diabetes mellitus and other metabolic imbalances
PL2403605T3 (en) Compositions comprising an aP2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]